Chapter 45: Antineoplastic Agents

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

If you are listening to this, you might want to find a quiet place, maybe grab a notebook and a strong coffee, because today we are not just skimming the surface.

We are hanging straight into the deep end of the pool.

We are essentially doing a Last Minute Lecture style deep dive into pharmacology, specifically Chapter 45.

Which, for those who haven't memorized the table of contents of Brenner and Stevens, is antinoplastic agents.

Exactly.

Or, as most of us know them, cancer drugs.

And I have to say, reading through this source material,

the stakes just felt immediately higher than usual.

It feels different than our usual topics.

There is a weight to it.

It is heavy material, both emotionally and scientifically.

I mean, you're dealing with cellular biology, complex chemistry,

and life or death clinical decisions all wrapped into one chapter.

It's dense, but it is incredibly important.

It really is.

I mean, the text opens with some statistics that just stop you in your tracks.

They really do.

It says cancer is the second most common cause of death in the U .S.

We are talking about

two million new cases a year.

Two million.

And 600 ,000 deaths annually.

And this one really got me.

The text states that approximately 40 % of men and women will be diagnosed with cancer at some point in their lifetime.

That is a staggering number.

Almost half the population.

It essentially means if you are in a room with two other people, statistics say at least one of you will face this diagnosis.

Right.

So the mission for today is pretty clear.

We need to demystify how we actually fight this thing.

We need to understand the weapons we use because looking at this chapter, it seems like we have moved from using blunt instruments.

Sledgehammers, maybe.

Sledgehammers.

That's what I was thinking.

From sledgehammers to very specific, high -tech sniper rifles.

That is a very accurate way to look at the history of oncology.

And we are going to walk through the chapter exactly as it is written.

We will start with biology of the enemy, what makes a cancer cell a cancer cell.

Then we will look at the cytotoxic drugs, those sledgehammers, the ones that kill rapidly dividing cells.

And finally, we will get into the targeted therapies, the new era of treatment.

And my role here is basically the curious student who is terrified of the chemistry.

A very important role.

I'll be asking the question that I think everyone wonders.

How do we kill the bad cells without killing the patient?

Because, spoiler alert, a lot of these drugs seem incredibly toxic.

They are.

And that is the central challenge of chemotherapy.

It is a balance of risk and benefit.

It is about finding a window where you can destroy the invader while leaving the host mostly intact.

Mostly intact.

Okay.

So let's unpack this.

Where do we start?

Let's start with the basics.

The text defines cancer as uninhibited new growth or a neoplasm.

But it makes a distinction right away between two main types.

We have solid tumors and hematologic malignancies.

Help me distinguish those.

Right.

This is the first fork in the road for any student of pharmacology.

Solid tumors are exactly what they sound like.

These are abnormal tissue growths.

So like breast cancer, lung cancer.

Exactly.

Breast, lung, prostate, colon.

These are masses of tissue that you can often see on a scan or feel physically.

Okay.

So that's the lump category.

Correct.

On the other hand, you have hematologic malignancies.

These arise in the bone marrow or lymph nodes.

These are the liquid cancers, right?

The liquid cancers, essentially.

So we are talking about leukemia, lymphoma, multiple myeloma.

Precisely.

These don't necessarily form a single solid ball.

Instead, they produce large quantities of abnormal blood cells that circulate throughout the body.

They just, they flood the system.

Okay.

So whether it is a lump or bad blood cells, the text lists four characteristics that make these cells malignant.

I want to run through these because they seem to define why cancer is so dangerous.

Good idea.

First, we have de -differentiation.

That refers to a loss of function and identity.

You have to remember, normal cells have a job.

A liver cell acts like a liver cell.

It filters toxins.

A skin cell acts like a skin cell.

Right.

It provides a barrier.

Cancer cells lose that specialized identity.

They kind of forget their job description.

They forget who they are.

Exactly.

They revert to a more primitive state where their only job is to survive and replicate.

They become parasitic.

They stop contributing to the welfare of the body and just start taking resources.

Which leads to the second characteristic, uncontrolled cell division.

They just won't stop splitting.

Correct.

Normal cells have social cues.

If they are touching other cells on all sides, what we call contact inhibition, they stop growing.

They know the room is full.

Right.

They stop.

Cancer cells ignore those cues.

They pile up on top of each other, forming a tumor.

And then you have invasiveness.

They don't respect boundaries.

A benign tumor might grow large, but it usually stays inside a capsule.

It pushes things out of the way.

A malignant tumor grows into the surrounding tissue.

It claws its way into the muscle, the nerves, or the organ next door.

And finally, the big one, metastasis.

Metastasis is the spread to other sites in the body.

This usually happens via blood vessels or the lymphatic system.

A cell breaks off from a breast tumor, travels through the blood, and lands in the brain or the bone.

And that's often what makes cancer so deadly.

And there's a specific concept mentioned in the text that facilitates all this, this growth and spread called angiogenesis.

Oh, this is crucial.

Think of a tumor as a rogue city being built inside the body.

A rogue city.

Okay, I like that.

As that city grows,

the people in the center, the cells in the center of the tumor, get too far away from the supply lines.

They're too far from the blood vessels.

They start to starve of oxygen and nutrients.

So the tumor would die from the inside out.

It would, unless it did something clever.

The tumor actually secretes growth factors, chemical signals that trick the body into building new blood vessels that feed it.

No way.

Yes.

It essentially builds its own highway system and water pipes right into the tumor.

That is angiogenesis, the creation of new blood vessels.

That is terrifyingly smart.

It plumbs itself into the main water line.

It is.

And as we will see later, preventing that stopping angiogenesis is a target for some modern drugs.

If you can cut off the supply lines, you can starve the city.

Okay.

So that's what the cell does.

But why does it do it?

The chapter dives into the genetics here and it feels like a battle between a gas pedal and a brake pedal.

That is the classic analogy for oncogenesis.

It helps to simplify the complexity of the genetics.

On one hand, you have proto -oncogenes.

Proto -oncogenes.

These are normal genes that help cells grow when you are healing a cut.

But if they mutate, they become oncogens.

Gas pedal gets stuck.

Exactly.

The gas pedal gets stuck to the floor.

The text mentions receptor tyrosine kinases, like EGFR.

EGFR is epidermal growth factor receptor.

Correct.

Imagine a switch on the outside of the cell that tells the cell, grow now.

In cancer, that switch gets stuck in the on position.

The cell thinks it's being told to divide constantly even when it isn't.

Okay, so we are speeding down the highway.

But usually a car has brakes.

Those are the tumor suppressor genes.

Their job is to stop cell division if something is wrong.

The most famous one mentioned in the text and one you absolutely need to know is P53.

P53.

The text says this is mutated in about half of all human solid tumors.

Right.

Half.

P53 is often called the guardian of the genome.

The guardian.

If a cell has damaged DNA, P53 spots it.

It hits the brakes.

It pauses division to let the repair crew fix the DNA.

And if the repair crew can't fix it.

Then P53 pulls the emergency cord.

It tells the cell to commit suicide.

Which is apoptosis.

Yes.

Programmed cell death.

It's a safety mechanism.

I am damaged.

I should not replicate.

I will delete myself.

But if P53 is mutated, if the brakes are cut, the cell keeps dividing even though it's damaged.

It passes those mutations onto its children.

And to make matters worse, the text says many tumors express BCL2 genes.

And BCL2 is?

It's an inhibitor of apoptosis.

It stops the cell from dying.

Exactly.

It's a gene that actively prevents the cell from dying.

So let's look at our car analogy again.

The gas pedal oncogenes is stuck down.

Right.

The brakes P53 are cut.

And now with BCL2, you've reinforced the chassis so the car can't be destroyed even if it crashes.

That is a formidable enemy.

So we have this biological runaway train.

Now we need to talk about how we engage it.

The text lays out the principles of cancer therapy.

The rules of engagement.

Yeah.

We have surgery and radiation, which are local.

And then we have drugs, which are systemic.

And that distinction is vital.

Surgery and radiation are great if the tumor is localized.

You cut it out or burn it out.

But remember, metastasis.

Right.

The spread.

If even a few microscopic cells have broken off and traveled elsewhere, what we call micrometastases,

local therapy won't get them.

You can't perform surgery on the entire body.

That's where the drugs come in.

They go everywhere the blood goes.

Exactly.

And we use them in specific strategies.

You might hear terms like induction, consolidation, and maintenance.

Break those down for me.

What is the difference?

Induction is the initial strike.

It's high dose intended to produce a rapid reduction in the tumor burden and improve symptoms.

The shock and awe phase.

You could say that.

The goal is to induce a remission where you can't detect the cancer anymore.

But we know hidden cells remain.

You just can't see them on a scan.

Right.

So then comes consolidation.

This is to complete or extend the remission, hopefully killing those micrometastases we just talked about.

Mopping up the stragglers.

And finally, maintenance.

Maintenance therapy is usually lower dose, long -term treatment designed to keep the cancer away for as long as possible.

It sustains the remission.

Now, there is a concept here that I found really interesting and a bit depressing, honestly.

The log kill concept.

It sounds like something from a video game, but it's actually math.

Yes.

This is a fundamental principle of chemotherapy kinetics.

You really need to get your head around this.

So if I have a billion cancer cells and I give a drug, it doesn't kill the specific number, like 100 million cells.

It kills a fraction.

Correct.

It follows first order kinetics.

It kills a percentage.

Say a specific dose kills 99 .9 % of the cells.

Which sounds great.

99 .9 % is an A plus.

If I cleaned 99 .9 % of my house, it would be sparkling.

In a math test, yes.

In oncology, not always.

Let's do the math.

If you have a hundred billion tumor cells, which is roughly a hundred gram tumor about the size of a small lemon.

Okay.

A hundred billion.

And you kill 99 .1%.

That's a three log kill.

You are left with 0 .1%.

Which sounds cool.

But 0 .1 % of a hundred billion is still a hundred million cells.

That is still a massive army of cancer cells.

I hadn't thought of it like that.

It is.

That is why we can't just give one dose.

We have to give repeated courses of therapy.

We knock it down from a hundred billion to a hundred million.

Then what?

We wait.

We hit it again to get it to a hundred thousand, then again to get it to a hundred.

We are whittling it down, hoping to get the number low enough that the patient's own immune system can wipe out the stragglers.

Why do we have to wait?

Why not just keep hitting it every day until it's gone?

Why give the cancer a chance to recover?

Because of toxicity.

These drugs kill normal cells too, especially bone marrow.

We have to use intermittent therapy cycles to allow the bone marrow in the patient to recover between rounds.

If we hit them continuously, we'd kill the patient along with the tumor.

It's a race.

We are betting that the normal cells will recover faster than the tumor cells.

That recovery period is key.

Now, before we get to the specific drugs, we have to look at figure 45 .1 in the text.

It's the cell cycle.

Oh, yeah.

I feel like this is a flashback to high school biology, but it seems really important for understanding when to use which drug.

It is critical.

To understand chemotherapy, you have to visualize the life of a cell.

It goes through phases, like a clock.

Okay, let's unpack the clock.

We started G1.

G1 is gap one.

The cell is preparing its gathering ingredients, making enzymes.

It is getting ready to work, bulking up.

Then it moves to the S phase.

Ask for synthesis.

This is the danger zone.

This is where DNA replication happens.

The cell unzips its DNA and copies the genetic code.

This is a huge target for drugs because if you mess up the copying process, the cell dies.

Okay, S phase is key.

Then we have G2, another prep phase, and finally M phase.

M for mitosis, the actual splitting of the cell into two daughter cells, the physical division.

Right.

Now, here is the distinction the text makes.

We have cell cycle specific drugs and cell cycle non -specific drugs.

So, specific drugs only work if the cell is in a certain slice of the pie.

For example, anti -metabolites usually hit the S phase.

They only kill cells that are actively copying DNA.

And if the cell is just hanging out, resting.

If a cell is resting in G1, the drug floats right past it.

It does nothing.

So, specific drugs act like snipers waiting for the target to walk by a window.

Exactly.

If the target doesn't walk by the window, if the cell isn't in S phase, the sniper misses.

This is why these drugs are effective for high -growth fraction tumors, where lots of cells are dividing, like leukemias.

And the non -specific drugs.

They are like broad -spectrum weapons or hand grenades.

They can hit the cell at any point, whether it is resting or dividing.

The alkylating agents we'll discuss later fall into this category.

They bind to DNA and damage it regardless of what the cell is doing.

Okay, so we have a strategy.

But the text warns us about why it doesn't always work.

Limitations.

And the biggest one is resistance.

It is the major cause of treatment failure.

Just like bacteria become resistant to antibiotics,

cancer cells become resistant to chemotherapy.

And there are two types, innate and acquired.

Innate means they were tough from day one, usually because of that P53 mutation we talked about.

Right, they were born resistant.

But acquired resistance is where the cancer evolves.

Evolution in real time, Darwinian selection happening right inside the patient.

The text uses a great example here involving something called P -glycoprotein or PGP.

This was figure 45 .2.

I love the visual this gave me.

Think of PGP as a bouncer at a club.

A bouncer, okay.

The cancer cell essentially installs these pumps, these bouncers, in its cell membrane.

The gene responsible is MDR1 or multidrug resistance 1.

So what does the bouncer do?

When the chemotherapy drug tries to get inside the cell to do its job, the P -glycoprotein grabs it and throws it back out.

Before it can even work, you're not on the list.

Get out.

Exactly.

It's an efflux pump.

The drug enters, gets pumped out, enters, gets pumped out, and never builds up a high enough concentration to kill the cell.

And it's multidrug resistance.

So one pump can throw out lots of different drugs.

That's the scary part.

It can throw out many different types of drugs.

Anthracyclines, taxanes, vinca alkaloids.

Suddenly your whole arsenal is less effective.

That is incredibly frustrating.

So the drug can't get in.

But even if it does, we have the other side of the coin.

Toxicity.

The cost of war.

The tech says most side effects happen because chemotherapy targets rapidly dividing cells.

Right.

And this is the key.

Chemotherapy isn't smart enough to know this is a cancer cell and this is a healthy cell.

It just looks for cells that are dividing fast.

It targets the action, not the identity.

So what else divides fast in the body?

Bone marrow cells.

They are constantly making new blood billions of cells a day.

Red cells, white cells, platelets.

So chemo hits the bone marrow hard.

Very hard.

It causes myelosuppression.

Which leads to?

A few things.

Leucopenia low white cells, which means a huge infection risk.

Thrombocytopenia low platelets, which means a bleeding risk.

You can bleed from just brushing your teeth.

And anemia low red cells, causing fatigue.

Okay.

What else divides fast?

The lining of your GI tract.

Your mouth, stomach, intestines.

That epithelium replaces itself constantly every few days.

So chemo kills those cells, leading to ulcers,

stomatitis, painful mouth sores, and diarrhea.

And hair follicles.

That's the one everyone knows.

Alopecia.

Hair grows fast.

Chemo attacks the follicles so the hair falls out.

And then there's the nausea.

The text mentions the chemoreceptor trigger zone.

What is that?

The CTZ.

It's a specific spot in the brain stem outside the blood -brain barrier.

Many of these drugs trigger it directly, causing severe nausea and vomiting.

So it's not just stomach irritation?

No.

It's a neurological signal to purge.

The body senses a toxin in the blood and tries to get rid of it.

It's a protective mechanism that backfires during chemo.

Okay.

We have set the stage.

We know the enemy, the strategy, and the risks.

Now, let's open the armory.

The text categorizes these drugs into groups.

The first group is the cytotoxic agents specifically.

The DNA synthesis inhibitors, also known as anti -metabolites.

The concept here is deception.

These drugs pretend to be nutrients.

The cell needs to build DNA things like folate, purines, pyrimidines.

So they're imposters.

They're imposters.

The cell grabs the drug, tries to use it as a building block, and it jams the gears.

The Trojan horse approach.

Let's start with the folate antagonist.

The big name here is methotrexate.

Methotrexate, or MTX.

It has been around for 70 years.

It's a workhorse.

It's a structural analog of folic acid.

Why does a cell need folic acid?

To make DNA, specifically, there is an enzyme called dihydrofolate reductase.

Dihydrofolate reductase, got it.

It converts dietary folate into the active form, tetrahydrofolate, that the cell needs to make thymidine, one of the DNA bases.

And methotrexate.

Methotrexate binds to that enzyme and inhibits it, shuts it down.

So no active folate, no thymidine, no DNA cell dies.

Correct.

Specifically, it dies in the S phase.

But remember, this stops normal cells from making DNA too.

That is why MTX can be very toxic to the bone marrow and GI tract.

The text mentions a rescue technique here.

Leucovorin.

Yes.

Leucovorin is folinic acid.

Basically, a pre -activated form of folate.

Here is the trick.

We give a huge toxic dose of methotrexate to kill the cancer cells.

A dose that would kill the patient.

Exactly.

Then we wait a bit, usually 24 hours.

Then we give it Leucovirin to rescue the normal cells.

How does that work?

How does it know to rescue the normal cells and not the cancer cells?

It's about timing and transport.

Normal cells can take up Leucovorin more efficiently.

More importantly, Leucovorin bypasses the block.

It doesn't need the enzyme that methotrexate blocked.

It provides the downstream product directly.

It's like giving the antidote right after the poison to save the host.

That is clever timing.

The text also mentions Pematrex, which works similarly, used a lot in lung cancer.

Yes.

Specifically, non -small cell lung cancer and mesothelioma.

It's another folate antagonist.

Next up are the Purine analogs, mercaptopurine and theoguanine.

These are false building blocks.

Purines, which are adenine and guanine, are two of the letters of the DNA code, A and G.

These drugs look like Purines, but aren't.

They get incorporated into the DNA and cause it to fail.

It's like putting a broken brick into a wall.

Now, there's a specific warning here, an interaction warning, that the text highlights regarding mercaptopurine and a guide drug called allopurinol.

This is a classic board exam question and a vital clinical point.

Okay, so this is important.

Very.

Mercaptopurine is broken down in the body by an enzyme called xanthine oxidase.

Okay.

Allopurinol is used to treat gout.

How does it work?

By inhibiting xanthine oxidase.

I see where this is going.

If a patient is on allopurinol for gout and you give them a standard dose of mercaptopurine, the chemo drug won't get broken down.

The enzyme that is supposed to clean it up is turned off.

So the chemo builds up.

To toxic, potentially fatal levels.

It can be fatal.

If you use them together, you have to lower the chemo dose drastically.

The text says by at least 50 to 75 percent.

If you don't, you could wipe out their bone marrow completely.

That is a life -saving detail.

Moving on to the pyrimidine analogs.

We have fluorosil or 5 -FU.

5 -FU, a very common one.

It inhibits an enzyme called thymidylate synthetase.

Another enzyme.

It effectively starves the cell of thymidine, another one of the four bases of DNA.

It is a workhorse for GI cancers, colon, stomach, pancreas.

The text notes distinct toxicities here.

It mentions skin toxicity and something called hand -foot syndrome.

Yes.

It's a strange reaction where the palms of the hands and soles of the feet get red, swollen, and painful.

It can even blister.

The drug seems to leak out of the capillaries in those areas.

And there's an antidote for overdose mentioned.

Uridine triacetate.

Right.

Similar to the leukovirin concept, it provides the missing building block, uridine, to save the patient from severe toxicity if they get too much 5 -FU, either by accident or design.

Then there is cidrobumbine.

Cidrobumbine is interesting.

It doesn't block the building blocks.

It stops DNA polymerase, the actual copier machine.

It gets incorporated and jams the whole process.

It's used heavily in leukemias.

And gemcitabine?

S -phase specific.

Used for pancreatic and lung cancer.

So you see, even within one class, different drugs have different niches.

Okay, let's move to the next major class.

We are done with the imposters.

Now we are on to the heavy hitters.

The DNA cross -linkers and intercalators.

These drugs don't pretend to be nutrients.

They physically damage the DNA.

They act like superglue or a crowbar, wrecking the double helix so it can't unzip or copy.

First up, the nitrogen mustards, which, yes, history buffs are related to the mustard gas of WWI.

They are.

The most widely used one is cyclophosphamide.

It's a cell cycle non -specific drug, meaning it hits the cell anytime.

It's a real broad spectrum powerhouse.

This one has a very specific, very nasty side effect involving the bladder.

Hemorrhagic cystitis.

Basically a bleeding, inflamed bladder.

It can be incredibly painful.

Why does that happen?

It's not the drug itself, it's a metabolite.

When the body breaks down cyclophosphamide in the liver, it produces a toxic waste product called acrolyne.

Acrolyne.

This acrolyne sits in the urine in the bladder and it's corrosive.

It eats away at the bladder lining.

And the fix.

A drug called mesna.

Mesna is given with the chemo.

It concentrates in the urine and it binds to that toxic acrolyne and neutralizes it.

It's like a chemical sponge that soaks up the poison before it can do damage.

So you're getting high dose cyclophosphamide, you're getting mesna.

Correct.

You have to protect the bladder.

Next in this group are the nitrocerias.

Carmostene.

What is special about carmostene is that it is highly lipophilic.

It loves fat.

And the brain is very fatty.

Exactly.

This means it can cross the blood -brain barrier.

Which is usually a fortress against drugs.

Exactly.

Most drugs bounce off the brain's defenses.

But carmostene can slide right through.

So it is one of the few drugs we can use to treat brain tumors.

The text even mentions it can be implanted as a wafer directly into the brain cavity after surgery.

Wow.

Okay, moving to the platinum compounds.

Cisplantin.

Cisplantin, a heavy metal drug.

It's an inorganic platinum complex.

It works by cross -linking DNA, specifically at the guanine bases.

It kinks the DNA strand so it can't be read.

But it comes with a laundry list of side effects.

The text calls out three big ones.

Nausea, nephrotoxicity, and ototoxicity.

It is arguably the most emetic, vomit -inducing drug we have.

We call it the vomit comet.

You have to give strong anti -nausea meds with it, or the patient will be miserable.

And nephrotoxicity is kidney damage.

Yes.

Severe kidney damage.

It can cause renal failure.

To prevent this, we hydrate the patient aggressively with IV fluids, sometimes for hours before and after.

We also use mannitol to keep the urine flowing, and sometimes a drug called sodium thiosulfate to neutralize the platinum in the kidneys.

And ototoxicity.

Hearing loss.

And unfortunately, that is often permanent.

It damages the hair cells in the inner ear.

Tinnitus, high frequency hearing loss.

It's a major problem.

That is rough.

Next up, we have the DNA intercalating drugs, the anthracyclines.

The most famous one is doxorubicin.

Often called the red devil, or the red death, because the liquid is bright red, and it turns the patient's urine red, which can be alarming if you don't warn them.

How does it work?

It's not just a cross -linker, is it?

No, it has a dual mechanism.

It intercalates.

It slides itself between the DNA -based pairs, like a shim, which stops replication, but it also generates free radicals.

It uses iron to create reactive oxygen species that slice the DNA up.

But those free radicals don't just stay in the tumor.

No.

And the heart is very susceptible to free radical damage.

That is the major dose -limiting toxicity of doxorubicin.

Cardiotoxicity.

It can cause irreversible heart failure.

Is there a way to stop it?

We limit the lifetime dose a patient can receive.

And in some cases, we use a drug called dexoroxane.

It's an iron slater.

It binds up the iron so the free radicals can't form in the heart.

It's a cardioprotectant.

OK.

One more in this section.

Bliomycin.

Bliomycin is unique.

It also breaks DNA via free radicals.

But unlike almost every other chemo drug, it causes very little bone marrow suppression.

That's good.

It is.

It means we can combine it with other drugs without wiping out the immune system, but has a specific toxicity to the lungs.

Pulmonary fibrosis.

Scarring of the lungs.

It can be fatal.

If a patient on Bliomycin develops a cough or shortness of breath, you have to worry.

So cyclophosphamide hits the bladder.

Cisplatin hits the kidneys and ears.

Doxorubicin hits the heart.

Bliomycin hits the lungs.

The pharmacology really is all about knowing which organ is at risk.

That is the art of oncology.

Mixing the drugs to kill the cancer without overlapping toxicities that would kill the organ systems, it's a balancing act.

OK.

That was a heavy section.

Let's move to section six.

Mitotic inhibitors.

These target the skeleton of the cell.

The microtubules.

Right.

We need to visualize this.

When a cell splits, it builds a scaffold, the mypotox spindle, to pull the chromosomes apart to the two new cells.

Think of it like a rope and pulley system.

The microtubules are the ropes.

They have to form, grab the chromosomes, pull, and then dissolve.

It's a dynamic process.

And we have two classes of drugs here that mess with ropes, the vinca alkaloids, vincristine and blastine, and the taxans, pachyletaxil, docetaxil.

And they work in opposite ways, which is fascinating.

Vinca alkaloids, which come from the periwinkle plant, block the assembly of the microtubules.

They prevent the ropes from being built.

No ropes, no division.

Right.

The cell gets stuck in metaphase and dies.

Taxanes, on the other hand, which come from the U -tree, block the disassembly.

They stabilize the microtubules.

So the ropes freeze.

They can't be taken down.

Exactly.

The cell builds the scaffold, but then it can't break it down to finish the division.

The cell gets stuck in mitosis and eventually dies.

Two different ways to sabotage the same machine.

Now, microtubules aren't just for cell division.

They're also used in nerves, right?

Like train tracks for transport.

Absolutely.

Which explains the key toxicity, neurotoxicity.

Especially with vincristine and pachyletaxil, patients get peripheral neuropathy tingling and numbness pins and needles in the hands and feet.

It's because the drug is messing with the internal transport system of the nerve cells, which relies on microtubules.

Got it.

Okay.

We have covered the traditional chemotherapy,

the sledgehammers.

Now we're entering the new era.

Section seven, small molecule inhibitors.

This is where pharmacology has exploded in the last 20 years.

Instead of just killing dividing cells, we are looking for specific broken proteins inside the cancer cell and designing a drug to fix or block just that one protein.

The text mentions that the names of these drugs tell you what they do.

We need a cheat sheet here.

Okay.

Here is your decoder ring.

If the drug ends in synib, it is a tyrosine kinase inhibitor.

Dash T -I -N -I -B.

Dnib, like imatinib.

Right.

If it ends in zomib, it is a proteasome inhibitor.

Zomib, like portizomib.

If it ends in cyclib, it inhibits cyclin -dependent kinase, CDK.

And parib is a PRP inhibitor.

The suffix tells you the mechanism.

Okay.

Let's talk about the drug that changed everything.

Imatinib or Gleevec.

Imatinib is the poster child for targeted therapy.

It treats a specific type of leukemia called CML chronic myeloid leukemia.

And this all goes back to something called the Philadelphia chromosome.

Yes.

In CML, two chromosomes, 9 and 22, swap a piece of DNA.

It's called a translocation.

This creates a mutant fusion gene called BCRABL.

And BCRABL acts like a bet.

It acts like a tyrosine kinase that is permanently stuck in the on position.

It's a growth signal that won't turn off.

It tells the white blood cells to divide, divide, divide.

And imatinib.

The imatinib was designed specifically to fit into the active site of that BCRABL protein and turn it off.

It's a custom -made key for a broken lock.

And because normal cells don't have that broken lock.

Exactly.

Because normal cells don't have BCRABL, the side effects are much, much milder than traditional chemo.

It turned a fatal disease into a manageable chronic condition.

It was a complete game changer.

That is incredible.

The text also highlights a case study box 45 .1 about melanoma.

This is a perfect example of genomic medicine.

The case describes a woman with metastatic melanoma.

They tested her tumor and found a specific mutation.

BRAFV600E.

Sounds like a license plate.

BRAFV600E.

It refers to a specific genetic error in the BRAF kinase, another one of these growth signaling proteins.

So what was the treatment?

The treatment wasn't just chemo.

It was a combination of two targeted drugs.

Diabrofenib, which is a BRAF inhibitor, plus trimetinib, which is a MEK inhibitor.

Why two?

Why not just hit BRAF?

Because the cancer is clever.

If you only block BRAF, it can find a way to reactivate the pathway downstream.

So they hit the same signaling pathway at two different points.

One hits BRF, one hits MEK, which is the next step down.

It creates a vertical blockage.

So you're cutting the wires in two different places.

Precisely.

It shuts down the growth signal much more effectively and, importantly, delays the development of resistance.

So they are sniping the command chain in two different levels.

Exactly.

Let's quickly touch on the other suffixes.

Proteasome inhibitors.

Bortezomib.

The proteasome is the cell's trash compactor.

It finds old or misfolded proteins and recycles them.

Bortezomib jams the trash compactor.

So the cell fills up with junk mail.

Fills up with toxic proteins, basically.

And the cancer cell dies from the stress.

This is huge in multiple myeloma, a cancer that makes a ton of protein.

And CDK inhibitors.

Pulbocyclic.

These inhibit cyclin -dependent kinases, which are the engines that drive the cell cycle forward.

These drugs stop the cell cycle right at the start, at G1.

They're used for a common type of breast cancer, ER -positive breast cancer.

And PRP inhibitors.

Rucoperib.

These are fascinating.

PIRP is an enzyme that repairs single -strand DNA breaks.

These drugs inhibit PRP.

So they stop DNA repair.

Right.

Now, here's the cool part.

They work best in cancers that already have trouble repairing DNA, like those with BRCA mutations.

From Brex to novarian cancer.

Right.

Those cells can't repair double -strand breaks.

So if you take away their ability to fix single -strand breaks with the pluripede inhibitor, any DNA damage becomes lethal.

It's called synthetic lethality.

You kick the leg out from under a stool that is already wobbling.

I love that image.

Finally, one last new drug mechanism.

Cellinexer.

Cellinexer blocks a protein called XP01.

This is a nuclear export protein.

We exit toward the nucleus.

Right.

Tumor suppressor proteins, the good guys, like P53, are supposed to be in the nucleus doing their job.

Cancer cells try to kick them out into the cytoplasm where they can't work.

Cellinexer locks the door so the tumor suppressors are trapped inside the nucleus where they can do their job and force the cancer cell to behave or die.

Amazing.

OK, final section.

Hormonal agents.

These aren't killing cells directly with poison.

They are starving them of the signals they need to grow.

Specifically for hormone -sensitive cancers like breast and prostate cancer.

For breast cancer, we have the CIRMS Tamoxifen.

Selective estrogen receptor modulators.

For breast cancers that are ER -positive, meaning they feed on estrogen, Tamoxifen blocks the estrogen receptor on those cells.

It cuts off the food supply.

Exactly.

But it's a modulator, not just a blocker.

What does that mean?

It means it has different effects in different tissues.

It's an antagonist, a blocker, in the breast.

But it acts like an agonist, a stimulator, in the uterus and in bone.

So while it treats breast cancer, it can slightly increase the risk of endometrial cancer, cancer of the uterine lining.

It's a trade -off.

Then we have S -orties, like full vestrant.

Selective estrogen receptor degraders.

They are pure antagonists.

They bind to the receptor and cause it to be degraded completely.

No mixed signal.

And aromatase inhibitors, like anastrazole or litrazole.

These are for postmenopausal women only.

After menopause, ovaries stop making estrogen, but fat cells and adrenal glands still make a small amount using an enzyme called aromatase.

These drugs block that enzyme.

Total estrogen deprivation.

And for prostate cancer, it's driven by testosterone.

So we use a few strategies.

One is GnRH agonists, like luprolide.

Wait, agonist?

Doesn't that mean it stimulates?

Why would you stimulate the system that makes testosterone?

It's a paradox.

It does, at first.

It causes a huge surge of stimulation to the pituitary gland.

But if you give it continuously, the gland essentially burns out.

It desensitizes and stops sending the signal to the testes to make testosterone.

The text mentions a flare because of this initial surge.

Yes.

When you first give it, testosterone spikes.

The tumor might grow briefly.

Patients might have more bone pain.

That's why you have to co -administer an androgen receptor antagonist, like flutamide or enzalutamide, for the first few weeks to block that initial flare.

Fascinating.

It's like screaming at someone until they stop listening.

That is a unique analogy.

But yes, it's all about desensitization.

And finally, corticosteroids like prednisone.

We usually think of these for inflammation, like for asthma or poison ivy.

But in high doses, they are lymphocytotoxic.

They directly kill lymphocytes, a type of white blood cell.

So they are very useful as part of regimens for leukemia and lymphoma, which are cancers of those cells.

Wow.

OK, we have made it through chapter 45.

From the biology of the beast to the sledgehammers of chemo to the sniper rifles of targeted therapy, and finally, the hormonal controls.

It is a massive landscape.

It's really a survey of the entire field of oncology in one chapter.

What is the big takeaway for you when you step back and look at all this?

For me, it is the shift in precision.

We started with drugs that just kill anything that grows, hence the hair loss and the gut issues and the bone marrow suppression.

That was the best we could do.

The sledgehammer.

The sledgehammer.

But now with things like imatinib and the BRA inhibitors, we're asking, what is the specific genetic typo driving this specific patient's cancer and designing a drug to target that typo and only that typo?

The text mentions an overwhelming abundance of new drugs.

It feels like the era of one size fits all chemotherapy is ending.

It is.

The future is a biopsy, a genomic sequence, and a custom cocktail of inhibitors tailored to that patient's tumor biology.

Which is hopeful.

It must be a very exciting time to be in this field.

It is very hopeful.

The progress in the last two decades has been absolutely breathtaking.

Here is a final thought for our listeners to mull over.

The text talks a lot about resistance.

We make a better drug.

The cancer builds a better pump or finds a new pathway.

It strikes me that we are in an evolutionary arms race inside the body.

We absolutely are.

So my question is, if the future is hyperspecialized drugs, are we also going to see hyperspecialized resistance?

Will the cancer evolve faster than we can invent new molecules?

Are we just training it to be smarter?

That is the multi -billion dollar question.

Can we checkmate the cancer before it flips the board?

Or are we always just one step behind?

Something to think about.

Thank you for joining the Last Minute Lecture team for this deep dive into antidiol plastic agents.

Stay curious and keep learning.

It's a fascinating subject.

See you next time.